Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age

Inclusion Criteria: 1. Male or non-pregnant female 18 through 85 years of age, both inclusive, at the time of study vaccine administration. 2. Provide written informed consent. 3. The subject is resident of the study area and is willing to comply with study protocol requirements, including availability for all scheduled visits of the study. 4. Healthy, as determined by medical history and clinical assessment of the investigator. 5. Female subjects of childbearing potential must have a negative urine pregnancy test within 24 hours prior to study vaccine administration. Exclusion Criteria: 1. Acute illness, at the time of study vaccine administration (once acute illness is resolved, if appropriate, as per investigator assessment, subject will be re-revaluated for eligibility). 2. History of any meningococcal vaccine administration. 3. Current or previous, confirmed or suspected disease caused by N. meningitidis. 4. Household contact with and/or intimate exposure to an individual with any laboratory confirmed N. meningitidis infection within 90 days prior to vaccination. 5. History of severe allergic reactions after previous vaccinations or hypersensitivity to any study vaccine component including tetanus, diphtheria and diphtheria toxoid (CRM197).